Chronic hepatitis B treatment is a worldwide problem that plagues doctors, and the cost of hepatitis B treatment is also a problem that plagues hepatitis B patients. Many hepatitis B patients may feel that they may not be able to afford the cost of hepatitis B treatment even though they want to receive regular antiviral treatment, but according to current treatment experience (as demonstrated by the guidelines for the prevention and treatment of chronic hepatitis B), antiviral treatment is essential for chronic hepatitis B. So, what can hepatitis B patients do to reduce the cost of treatment? The first thing that hepatitis B patients should learn is to recognize the right door, which means that they should find a regular medical institution for treatment. Because chronic hepatitis B treatment is a worldwide problem, there are quite a few scammers, and once patients fall for them, one is to let the scammers cheat you out of your already limited treatment costs, so that you can find a regular hospital with no money available, and the other is to possibly delay diagnosis and treatment. So how to recognize the true face of the scammers? The overall goal of chronic hepatitis B treatment is to maximize long-term inhibition of hepatitis B virus, reduce hepatocyte inflammation necrosis and liver fibrosis, delay and reduce the occurrence of liver failure, cirrhosis, liver cancer and its complications, thereby improving quality of life and prolonging survival time. From this goal, we can see that the treatment of chronic hepatitis B is hierarchical, with different treatment goals for patients at different stages. There are two main factors that affect the cost of hepatitis B treatment: one is the condition of the hepatitis B patient himself; the other is the hepatitis B treatment method. And because of these two factors, we can’t tell each patient exactly how much hepatitis B treatment will cost. Therefore, all those advertisements that guarantee “three months to cure” and “three thousand dollars to guarantee good treatment” are not to be trusted. The second thing is that patients should use their medication strictly according to medical advice. At present, patients can be roughly divided into two categories, one is through the network, books on hepatitis B related knowledge, they have been psychologically and economically prepared before choosing a treatment plan, compliance is also relatively good. However, because they are not professionals, they may not know much about it and may mistakenly believe that a certain drug or treatment method is the most suitable; while the other group has little knowledge about hepatitis B. They demand “good drugs” and “fast-acting drugs”. “They do not consider the psychological and economic burden of long-term medication, and change doctors or medications on their own once they have poor efficacy or resistance or are financially difficult to support. It is not known that changing medication or stopping medication on your own may lead to the development of drug resistance, and may also lead to hepatitis attacks and rapid deterioration of the disease. This can lead to greater problems, both physically and financially. Thirdly, it is important to look at the cost correctly. There are a number of antiviral drugs on the market today, and the characteristics and prices of each vary widely. From the point of view of market economy alone, it is natural that the stronger the antiviral ability and the lower the incidence of drug resistance, the higher the price of drugs, while the price of drugs with weak antiviral ability and high incidence of drug resistance is correspondingly lower. However, each patient’s condition is different and may be at a different stage of the disease, so the cost of hepatitis B treatment varies considerably. Patients may have the idea that they can start with lower priced drugs for the first time, and then consider switching to more effective drugs if they are ineffective or resistant to them. For hepatitis B drugs, the cost effectiveness should be evaluated, not only on price, but also on the patient’s condition, possible efficacy, drug resistance, safety and many other issues. To put it simply, it is important to consider “cost effectiveness”. In addition to the cost of antiviral drugs, the cost of hepatitis B treatment also includes all the costs incurred during the entire treatment process, such as the cost of examinations, the cost of additional drugs that may be added after drug resistance, the cost of lost work and hospitalization after recurrence of the disease, etc. Therefore, when considering the cost, it is important to look at the whole picture. Fourth, for hepatitis B virus carriers, the most common question asked by patients is: My viral load is so high, why not treat it? That is because current treatment regimens are very ineffective for antiviral therapy in such cases. For carriers characterized by high viral load with persistently normal liver function, even antiviral therapy with the most potent nucleoside (acid) analogs can result in significant viral decline during treatment, but rapid rebound once the drug is discontinued. Although viral load is correlated with the prognosis of patients with hepatitis B, patients are unlikely to be on medication for life, so withholding treatment is currently advocated. Of course, the absence of antiviral therapy does not mean ignoring it, and patients still need to have regular checkups (usually once every six months or so). In the case of special conditions such as cirrhosis, antiviral treatment should be considered in a timely manner. In conclusion, in order to reduce the cost of hepatitis B treatment, patients should go to a regular medical institution, and through the consultation of a specialist, choose reasonable antiviral drugs and develop a practical and standardized individualized treatment plan according to the patient’s condition (gender, age, viral load, transaminase level, liver histological examination, etc.), economic status, and personal wishes, with full communication between the doctor and patient.